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Abstract The production of superoxide and nitric oxide individ- 
ually has been associated with the development of several diseases 
but only recently has it been realised that interactions between 
them may also be important in disease pathology. The central 
hypothesis which is emerging is that the balance between nitric 
oxide and superoxide generation is a critical determinant in the 
aetiology of many human diseases including atherosclerosis, neu- 
rodegenerative disease, ischaemia-reperfusion a d cancer. These 
ideas are discussed in this short overview and placed in the context 
of the current and future status of therapies which could modulate 
the balance between nitric oxide and superoxide. 
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1. Introduction 
Oxygen and nitrogen together comprise over 98% of the air 
we breathe. Despite being essential for most forms of life, the 
high content of oxygen in the atmosphere means that oxidation 
reactions are commonplace in our environment. Although our 
body uses oxygen and oxidation reactions to good effect for 
generating energy and killing invaders, we cannot avoid some 
of the unwanted side reactions, which are caused by partially 
reduced forms of oxygen and result in the physiological equiv- 
alents of rusting and rancidity. In recognition of the important 
role that oxygen-derived species play in biology, they have 
often been grouped together and called reactive oxygen species 
(ROS) [1]. This global term includes both oxygen radicals and 
non-radical derivatives of oxygen (Table 1). Many ROS can 
modify essential biological molecules uch as lipids, proteins 
and DNA, leading to changes in function. 
Nitrogen also plays a central role in biology and is incorpo- 
rated into all of the major classes of biomolecules. However, 
it is only recently that a physiological role for reactive nitrogen 
species (RNS: Table 1) has been appreciated following the 
discovery that the simplest compound of nitrogen and oxygen, 
nitric oxide (NO') is produced in vivo. Nitric oxide has an 
astounding range of biological roles including modulation of 
vascular tone, memory formation and inflammation [2 6]. NO 
often achieves these effects by binding to the haem group of the 
soluble form of the enzyme guanylate cyclase, but rarely 
through irreversible chemical modifications of other molecules. 
However. one important function of NO" is thought to be in 
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the macrophage-dependent killing of parasites, and possibly 
cancer cells, indicating the potential of this free radical to medi- 
ate cytotoxic and pathological effects [5]. 
Here we describe an emerging picture which suggests that the 
interactions between RNS and ROS generate potentially cyto- 
toxic agents which may mediate some of the pathology associ- 
ated with Parkinson's disease, chronic inflammation, athero- 
sclerosis and cancer. Some of the complex chemical interactions 
between ROS and RNS which have already been described in 
the literature are shown in Fig. 1. 
It is evident from this scheme that some RNS may normally 
be useful but can be toxic in excess. Nitric oxide is the prime 
example. Other RNS such as nitrogen dioxide (NO~) and per- 
oxynitrite (ONOO)  are probably always damaging. The same 
appears to be true for ROS; superoxide (O:') is often useful but 
the hydroxyl radical (OH) is probably always bad. An added 
complexity is that some of the endogenous defence mechanisms 
against he damaging RNS may lead to the generation of poten- 
tially cytoprotective species uch as the nitrosothiols (RSNO in 
Fig. 1 ). However, it is evident hat the hahmce between NO" and 
ROS (especially O)') at sites of injury can affect he net outcome, 
and may, therefore, be a key determinant of whether the result 
of tissue injury is resolution and repair, or chronic inflamma- 
tion. 
2. RNS/ROS interactions 
Levels of NO" in excess of that required to activate guanylate 
cyclase can inhibit glycolysis, the mitochondrial respiratory 
chain and DNA replication [5,7- 13]. These effects can be direct, 
eg inhibition of ribonucleotide reductase [10] and mitochon- 
drial cytochrome c oxidase [7] but often they involve NO" inter- 
actions with ROS. Nitric oxide reacts very rapidly with oxygen 
radicals. Thus NO" reacting with O~" generates ONOO.  This 
species may mediate several of the cytotoxic effects of NO', 
such as the destruction of feS centres in enzymes. Persistent 
blockade of cytochrome c oxidase by NO" may lead to the 
release of free calcium ions from the mitochondrial matrix into 
the cell cytosol [12]. Nitric oxide also reacts with lipophilic 
peroxyl radicals, important propagating species in the biologi- 
cal chain reaction of lipid peroxidation, 1o generate alkyl per- 
oxynitrates (LOONO). These appear far more stable than 
ONOO- [13]. If LOONO derivatives can be metabolised with- 
out the release of toxic free radicals then the reaction of NO" 
with peroxyl radicals is potentially beneficial because it allows 
NO" to stop lipid peroxidation. The ratio of NO" to ROS may 
be all important since ONOO- can cause lipid peroxidation. 
Thus, a 1 : 1 ratio of O~ to NO" generates ONOO and induces 
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Fig. 1. Origins and interactions ofROS and RNS in biological systems. 
The most important route for the formation of RNS is the oxidation 
of arginine by NO" synthases (NOS) which are essentially of 2 types. 
These are the constitutive calciundcalmodulin-dependent forms 
(cNOS), which produce low levels of NO', and inducible (iNOS) forms 
which have tightly bound calmodulin, are permanently active, and 
capable of generating high levels of NO ° . The major sources of 02" in 
vivo, are shown and include; mitochondrial respiration, NADPH oxi- 
dases; a family of enzymes which catalyse the vectorial synthesis of 02" 
from oxygen, the enzyme xanthine oxidase which catalyses the forma- 
tion of 0-2 °and HzO z from oxygen and xanthine or hypoxanthine. The 
different RNS that may directly contribute to the pathogenesis of dis- 
ease are (ONOO-; peroxynitrite, NO2*; the nitronium cation which 
results in nitration of tyrosine residues, and NO~, which may mediate 
a number of pro-oxidant reactions including nitration). Those RNS 
with potentially beneficial effects include NO" itself, the adducts formed 
from the termination reaction of NO" with peroxyl radicals (LOONO) 
and nitrosothiols (RSNO) formed from the reaction of peroxynitrite 
with thiols). Nitric oxide reacts directly with oxygen to form NO~ but 
this third-order reaction is very slow at physiological concentrations of 
NO ° and ultimately ields nitrite [38]. 
lipid peroxidation whereas an excess of NO ° can inhibit lipid 
peroxidation by scavenging peroxyl radicals [13]. 
3. Relevance to haman disease 
3.1. Cardiovascular disease 
Vascular endothelial cells generate NO" for a multitude of 
physiological reasons and they may also secrete O~" [2,14]. 
Hence ONOO- (Fig. 1) can form in the vasculature. Phagocytes 
adhering to vascular endothelium can also produce RNS and 
ROS and interactions between them may have regulatory sig- 
nificance, e.g. NO" inhibits platelet and phagocyte adhesion to 
the endothelium [2,6]. In advanced atherosclerotic lesions 
thrombosis plays an important role and this normally beneficial 
biological process is controlled in part by the NO°-dependent 
inhibition of platelet aggregation [2]. However, in atheroscle- 
rotic lesions excess production of 02  ° may cause loss of the 
modulatory action of NO ° and at the same time yield ONOO- 
which is pro-aggregatory and so could commit platelets in this 
environment to thrombus formation [15]. 
In inflammation the balance between NO ° and O~ ° is altered 
during the interplay of the numerous mediators released in this 
process, but it must return to normal for resolution and healing. 
Failure to normalise may be an important factor predisposing 
to chronic inflammation. Atherosclerosis may be one example 
where this occurs. At an early stage in the development of this 
disease, chemical transformation of low density lipoprotein 
(LDL) occurs in the vessel wall [16]. Lipid peroxidation is one 
way in which LDL modification occurs and it results in the 
formation of a rancid mixture of toxic products. Probably in 
an attempt at protection, modified LDL is engulfed by macro- 
phages; the resulting lipid laden foam cells may then become 
part of the problem because of the effect of their secretory 
products on other cells in the lesion, e.g. encouraging smooth 
muscle cell proliferation [16]. We do not really know how oxi- 
dation of LDL begins in the artery wall. However, peroxynitrite 
could be involved since it efficiently oxidises LDL [17,18], 
causes a rapid depletion of several antioxidants (ascorbate, 
urate, protein thiols and ubiquinol) [19] and releases copper 
ions from the plasma protein caeruloplasmin [20]. Copper ions 
are powerful catalysts of LDL oxidation which have been de- 
tected in advanced human atherosclerotic lesions [21,22]. Con- 
sistent with formation of ONOO- in the vasculature, im- 
munoreactive material which cross-reacts with an antibody 
recognising nitrotyrosine (Fig. 2) has been found in human 
atherosclerotic lesions [23]. 
The changes which occur during atherosclerosis also include 
loss of the primary function of the vessel in acting as a conduit 
of variable size for blood. Early in hypercholesterolaemia a 
profound endothelial dysfunction appears; the responses to the 
normal vasodilatory effects of NO" are lost through a shift in 
the balance between NO" and O2" towards the latter [14,18]. As 
predicted from this hypothesis the 02  scavenging enzyme super- 
oxide dismutase (SOD), diminishes this endothelial dysfunc- 
tion, as does the substrate of the NO" synthases, c-arginine 
[18,24]. If the balance between the generation of NO" and O~" 
in the vasculature can be 'reset' with either arginine or SOD, 
one would expect hat decreasing NO" synthesis would be pro- 
atherogenic, as has been reported [25]. Furthermore, it has 
Table 1 
Reactive oxygen species (ROS) 
Radicals Non-radicals 
Superoxide, O~" 
Hydroxyl, OH ° 
Peroxyl, LO~ 
Alkoxyl, LO ° 
Hydroperoxyl HO~ 
Hydrogen peroxide, H202 
Hypochlorous acid, HOCL* 
Ozone, 03 
Singlet oxygen LAg 
Lipid peroxides 
Reactive nitrogen species (RNS) 
Radicals Non-Radicals 
Nitric oxide**, NO" 
Nitrogen dioxide, NO~ 
Nitrous acid, HNO2 
Dinitrogen trioxide NzO3 
Dinitrogen tetroxide N204 
Peroxynitrite, ONOO- 
Alkyl peroxynitrites LOONO 
A free radical is any species capable of independent existence containing 
one or more unpaired electrons; it is denoted by a superscript dot. 
Reactive is a relative term: NO" and 02 ° are poorly reactive whereas OH ° 
reacts with everything. The other species have intermediate reactivities. 
NO" and 02" are similar in other respects; they both have important 
physiological roles but are toxic in excess, often by generating other 
oxidants. Ironically, O~" is one of the few molecules with which NO ° 
reacts quickly (and vice versa). 
*Could equally well be called a 'reactive chlorine species'. **The correct 
chemical name for nitric oxide is nitrogen monoxide. However, com- 
mon usage generally prevails in these matters as a brief search on 
Medline with these two terms will soon confirm. 
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Fig. 2. Detection of RNS-induced amage detection of short-lived and 
reactive species uch as many of the RNS is difficult but some of the 
reaction products are stable. One important example is nitration of 
aromatic amino acids, which occurs by their reaction with ONOO , 
probably via NO~ and NO~. Tyrosine is especially sensitive, giving a 
nitrotyrosine adduct which can be measured by HPLC [19,32] (directly 
or after eduction to aminotyrosine, which can be detected electrochem- 
ically, giving increased sensitivity), by GC/MS or by antibodies directed 
against nitrated proteins [23]. Nitrotyrosine is excreted inhuman urine 
and as such might be useful as a total body marker of RNS [54]. Other 
potential markers for RNS include nitrate/nitrite, nitrosothiols, oxida- 
tion of oxyhaemoglobin, depletion of antioxidants, deaminated DNA 
bases, 8-nitroguanine and the formation of end-products of the reac- 
tions of RNS with LO~ and RO" during lipid peroxidation, such as 
LOONO (Fig. 1). 
recently been shown that oxidised LDL decreases the expres- 
sion of endothelial NO ° synthase [26]. It is attractive to hypoth- 
esize that the loss of endothelial NO" production plays a role 
in phagocyte adhesion and activation at sites of injury, as oc- 
curs after ischaemia-reperfusion [27]. 
3.2. Protective mechanisms 
Several antioxidants can scavenge ONOO- [19], The interac- 
tions with thiols is of particular interest: ONOO can irre- 
versibly oxidise them to higher oxidation states, but nitrosothi- 
ols can also form which may later act as NO" donors [15,28]. 
Indeed, when isolated vascular tissues are exposed to ONOO-, 
vasorelaxation ccurs by a mechanism characteristic of release 
of NO" from a 'carrier molecule' such as a nitrosothiol [28,29]. 
Repeated exposure to ONOO results in a progressive decrease 
in the efficiency of the vasorelaxing effect and inhibition of the 
ability of the heart o respond to other vasorelaxing a ents uch 
as isoproterenol r prostacyclin [29]. These data suggest hat 
ONOO- may overwhelm thiol-dependent protective mecha- 
nisms, leading to ONOO -dependent vascular dysfunction. An- 
other potential protective mechanism would be the removal of 
O~, °by the enzyme superoxide dismutase (SOD). However, the 
rate of reaction between NO ° and O¢ is so fast that is is effec- 
tively only limited by the rate of diffusion of the two radicals. 
For SOD to be effective it must, therefore, be at a concentration 
comparable to or higher than NO ° and close to the site of 
NO'/O $ generation. Control of the 03"/NO" reaction may be the 
function of the 'extracellular' SOD enzymes which bind to 
endothelial cell surfaces and the arterial intima [30]. 
If the O2"/NO" balance isrestored in favour of NO', the result 
could be inhibition of LDL oxidation by reaction with peroxyl 
radicals [13,31]. How effective is NO" as a peroxyl radical scav- 
enger? We can compare it with et-tocopherol which scavenges 
peroxyl radicals about 10,000 times faster than peroxyl radicals 
can recruit unmolested fatty acids into the cycle of lipid perox- 
idation. Although the concentration f ~-tocopherol (30/aM in 
plasma) is approximately 100 times higher than the average 
concentration f NO" in the artery wall (approx. 0.1-0.4/aM) 
NO" reacts with peroxyl radicals with a rate constant of approx- 
imately 1 x 10 ~ M -~ .s ~ which is 10 3 times higher than the scav- 
enging of these radicals by a-tocopherol. This simple and rather 
conservative calculation suggests that NO" is a more effective 
antioxidant than vitamin E. However, the biological properties 
of the lipid-peroxyl-nitric oxide adducts (LOONO, Fig. 1) re- 
main to be characterised before we can assess the overall con- 
sequences of this reaction. 
3.3. Inflammation 
ROS and RNS play important roles in killing foreign organ- 
isms and in acute inflammation but their over-production may 
cause tissue damage and vascular leakage in septicaemia, rheu- 
matoid arthritis and inflammatory bowel disease [2,6,30]. The 
precise mechanisms of these cytotoxic effects are unknown but 
RNS are implicated since nitrotyrosine (Fig. 2t has been de- 
tected in serum and synovial fluid from rheumatoid patients 
[32] and co-localises with NOS in a guinea pig model of chronic 
gut inflammation [33]. Furthermore, intra-colonic instillation 
of peroxynitrite can produce colitis in rats [34] and patients with 
active ulcerative colitis show a marked increase in NOS activity 
in the inflamed colonic mucosa [35]. Septicaemia s associated 
with the induction of NOS in several cell types in response to 
mediators uch as cytokines [6]. The iNOS isoenzymes are ca- 
pable of sustaining high rates of NO" production (see Fig. 1). 
In addition to the well recognised effects of NO" in causing 
hypotension i this syndrome, vascular damage may also arise 
from RNS [2]. Acute respiratory distress yndrome (ARDS) 
which often results from severe infection, may also involve 
RNS generation i  the lung as evidenced by the presence of 
nitrotyrosine [36]. 
3.4. RNS and cancer 
Although RNS may be used by phagocytes to kill cancer 
cells, it is ironic that, like ROS, they have many of the charac- 
teristics of carcinogens [37,38]. Structural alterations in the 
DNA, e.g. base pair mutations, rearrangements, deletions, in- 
sertions and sequence amplification can be induced by ROS 
(OH', ~O 2, RO~, RO', 03) and several RNS (HNO> ONOO ) 
[1,37,39]. Nitrous acid deaminates DNA bases whereas 
ONOO- and products derived from it may well act as deami- 
nating, nitrating and nitrosating agents, forming such species 
as 8-nitroguanine. RNS could cause alterations incell signalling 
and may alter cytoplasmic and/or nuclear signal transduction 
pathways, e.g. nitration of tyrosine (Fig. 2) may prevent he 
action of tyrosine phosphatases and kinases. NO', perhaps 
formed by NO" synthases produced in the tumour could facili- 
tate turnout growth by promoting angiogenesis. Indeed in- 
creased induction and activity of NOS in human gynecological 
cancers is correlated with increased malignancy [40]. 
3.5. Neurodegenerative disease 
High levels of NO" have been implicated in the pathology of 
Alzheimers disease, the consequences of viral infections of the 
CNS and in the excitotoxic neuronal death that is known to 
play a role in stroke and several neurodegenerative diseases 
[4143]. Activation of the glutamate receptors triggers calcium 
influx into the cell, which stimulates the activity of calcium/ 
calmodulin-dependent neuronal NOS under conditions where 
ROS formation is also enhanced. It follows that ROS/RNS 
interactions may also be important in these effects on the CNS. 
Microglial cells are essentially macrophages resident in the 
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brain and might be expected, on activation, to generate RNS 
as well as ROS. It is possible that reversible inhibition of cyto- 
chrome c oxidase by NO" leads to increased O~" formation in 
mitochondria, ONOO- formation and resultant damage to FeS 
centres [7,8,11]. This idea is consistent with a role for both RNS 
and ROS in the impairment of mitochondrial function known 
to be associated with Parkinson's disease and possibly impor- 
tant in Alzheimers. 
A connection between the neurological disorder amyotro- 
phic lateral sclerosis (ALS), ONOO- and SOD has been sug- 
gested [44,45]. Patients with the familial dominant form of this 
disease (about 10% of the total patients) have mutations in 
Cu/Zn-SOD which could decrease nzyme activity by 40-60%. 
One hypothesis i that mutated SODs might promote damage 
to motor neurone cells by ONOO- dependent nitration of pro- 
teins [45]. 
4. Prospects for therapy: striking a balance 
From the arguments outlined above it is evident hat thera- 
peutic intervention is confounded by not knowing at the outset 
whether the optimal strategy is to enhance or inhibit NO" for- 
mation. Clearly, a sound understanding of the pathological 
process is needed prior to intervention, perhaps utilising mark- 
ers of RNS dependent damage outlined in Fig. 2. Below we 
outline some of the approaches which are either currently avail- 
able or in development. 
4.1. Nitric oxide synthase inhibitors 
Under conditions where excess generation of NO" is contrib- 
uting to the tissue damage, inhibition of NOS would seem to 
be a reasonable therapeutic strategy. However, given the wide- 
spread function of NO" in the body it would probably be advan- 
tageous if selective inhibition of the specific isozyme of NOS 
which is contributing to the disease process can be achieved 
[46]. Considerable progress has been made in the development 
of such compounds. For example, potent selective inhibitors of 
iNOS such as N-iminoethyl-e-lysine have been shown to sup- 
press adjuvent induced arthritis in rats [47] and similar com- 
pounds are being considered for treatment of life threatening 
hypotension i septicaemia [2]. Similarly, selective nNOS inhib- 
itors may be valuable in treating stroke. Other less selective 
inhibitors may be useful in an intensive care setting, where 
potential side effects such as hypertension can be carefully 
monitored. 
4.2. Nitric" oxide donors 
Nitrovasodilators such as glycerol trinitrate have been 
known for years to be metabolised by vascular smooth muscle 
cells to release NO'. They provide immediate relief from the 
pain of angina by relaxing the constricted coronary vasculature. 
Their effects are short term because they induce tolerance prob- 
ably through a O2-'-dependent mechanism [48]. New genera- 
tions of NO" donors may allow selective release of NO" in 
difl'erent tissues and local restoration of the balance between 
RNS and ROS. For example, nitrosoglutathione appears to 
show platelet selective effects when administered in vivo 
whereas the classical organic nitrates have little or no effect on 
platelets at therapeutic doses [49]. The clinical indications of 
such compounds may then be much broader than angina and 
could include prevention of the re-occlusion of coronary after- 
ies after angioplasty [50] and arresting premature labour [51]. 
Interestingly NO" itself is being used in the treatment of pulmo- 
nary hypertension [52]. 
Arginine administration may also have beneficial effects by 
enhancing NO" formation in the vasculature [24]. Several die- 
tary antioxidants can inhibit ONOO -dependent damage; they 
include ascorbate and vitamin E [19]. Our knowledge of dietary 
effects on RNS in vivo is clearly in its infancy. 
4.3. Scavenging of O~ 
One obvious way to restore the balance between NO" and O~" 
would be to use SOD or SOD mimetics. However, because of 
the rapid reaction between NO" and O~" localisation of the 
enzyme or compound to the vascular endothelium will be nec- 
essary. One approach is to use recombinant EC-SOD itself or 
genetically engineered SOD containing a heparin binding site 
[531. 
5. RNS: the future 
In this minireview we have focussed on the emerging ideas 
of how the balance between RNS and ROS may play a role in 
human disease, the insight and opportunities this provides for 
applying and understanding established therapies, and the ap- 
proaches this may suggest for developing novel drug candi- 
dates. An area we have not addressed in any detail, yet is 
probably destined to take centre stage, is the effects of the 
changing RNS/ROS balance on the molecular events which 
control cell signalling and gene expression. From these studies 
it may emerge that under non-pathological conditions the 
RNS/ROS balance may play an important role in controlling 
cell growth, motility and life span. 
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